trending Market Intelligence /marketintelligence/en/news-insights/trending/pjs48jp5xqwdm-b0xluneg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Dermira adds new board member

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles


Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018

Dermira adds new board member

Dermira Inc. increased the size of its board to 10 directors from nine and elected Emmanuel Caeymaex as a class II director, effective Jan. 1, 2017.

UCB Pharma SA, which is entitled to designate one member to Dermira's board as part of a development and commercialization agreement, designated Caeymaex as its new designee to the board to replace Mark McDade.

Caeymaex is the executive vice president of immunology and patient value unit head of UCB Pharma's parent UCB SA. McDade, formerly an executive vice president and COO of UCB SA, was the previous designee under the agreement.